TP53

TP53
Thomas Splettstoesser · CC BY-SA 3.0 · source
Name	TP53
Organism	Homo sapiens
Chromosomal location	17p13.1
Aliases	P53; tumor protein p53

TP53 TP53 encodes a crucial human tumor suppressor protein initially characterized for roles in cell cycle control, DNA damage response, apoptosis, and senescence. Discovered through studies involving Harvard University investigators and early work at Cold Spring Harbor Laboratory, TP53 has become central to cancer biology, clinical oncology, and therapeutic research programs at institutions such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. The TP53 pathway links signaling from kinases like ATM and ATR to transcriptional regulation affecting genes such as CDKN1A (p21) and BAX.

Function and Mechanism

TP53 functions primarily as a sequence-specific transcription factor that binds response elements in promoters of target genes to regulate cell cycle arrest, DNA repair, apoptosis, and metabolism. In response to genotoxic stress from agents studied by researchers at National Cancer Institute and University of Cambridge, sensor kinases including ATM, ATR, and CHK2 phosphorylate TP53 leading to stabilization and activation. Activated TP53 transactivates effectors like CDKN1A, MDM2 (which forms a feedback loop), and PUMA, coordinating outcomes ranging from transient arrest to programmed cell death, processes investigated in clinical trials at Dana-Farber Cancer Institute.

Structure and Genomic Context

Human TP53 maps to 17p13.1 within a genomic neighborhood scrutinized by groups at The Sanger Centre and Broad Institute. The 393–amino-acid protein contains an N-terminal transactivation domain, a central DNA-binding domain defined by high-resolution structures solved by teams at European Molecular Biology Laboratory and Max Planck Institute, and an oligomerization domain near the C-terminus required for tetramer formation. TP53 gene architecture includes multiple promoters and alternative splicing events characterized by investigators at Cold Spring Harbor Laboratory and University of Oxford, producing isoforms investigated by researchers at Institut Pasteur.

Role in Cancer and Tumor Suppression

TP53 is frequently described as "guardian of the genome" in publications from The Francis Crick Institute and remains the most commonly altered gene in human tumors studied at Memorial Sloan Kettering Cancer Center. Loss of TP53 function contributes to tumorigenesis across cancers catalogued in efforts by The Cancer Genome Atlas and International Cancer Genome Consortium, including lung cancer cohorts from Johns Hopkins University and breast cancer studies from Christie Hospital. Restoring TP53 pathway activity is a therapeutic strategy pursued in trials at MD Anderson Cancer Center and biotechnology programs inspired by discoveries at Stanford University.

Mutations and Clinical Significance

Somatic and germline mutations affecting the DNA-binding domain predominate in datasets curated by Catalogue Of Somatic Mutations In Cancer and influence prognosis in colorectal studies from Mayo Clinic and glioma registries at Massachusetts General Hospital. Germline TP53 mutations underlie Li–Fraumeni syndrome described by clinicians at St. Jude Children's Research Hospital and managed through surveillance protocols developed with National Institutes of Health support. Hotspot substitutions such as those reported by Karolinska Institute and University College London researchers can produce dominant-negative or gain-of-function effects that alter responses to chemotherapy regimens evaluated at Royal Marsden Hospital.

Regulation and Interacting Proteins

TP53 activity is tightly regulated by interactions with proteins including the ubiquitin ligase MDM2, cofactor MDM4, acetyltransferases studied at Yale University such as CBP/p300, and chromatin remodelers characterized by groups at Cold Spring Harbor Laboratory. Post-translational modifications by kinases from Salk Institute and phosphatases identified at RIKEN modulate stability and specificity. Viral oncoproteins from Human papillomavirus and adenovirus proteins characterized at Centers for Disease Control and Prevention disrupt TP53 through direct binding, informing vaccine and antiviral research at Bill & Melinda Gates Foundation-supported programs.

Model Organisms and Experimental Studies

Mouse models with Trp53 knockout or specific point mutations generated at The Jackson Laboratory and experimental data from zebrafish facilities at European Zebrafish Resource Center have illuminated TP53 roles in development and tumor suppression. Yeast-based functional assays developed at Whitehead Institute and biochemical reconstitution studies performed by teams at Max Planck Institute complement patient-derived xenograft work at National Cancer Institute repositories. Clinical translational studies at University of California, San Francisco leverage insights from these models to design targeted therapies and immunotherapy combinations evaluated in consortium trials with American Association for Cancer Research participation.

Category:Genes